Cardiff Oncology (CRDF) said Tuesday that preliminary results from a mid-stage study of its cancer treatment candidate onvansertib showed an overall 57% objective response rate, or ORR, in patients with a specific metastatic colorectal cancer.
Patients who received a 30 milligram dose of onvansertib in addition to standard of care had a 64% ORR, while those who received 20 milligram plus standard of care had a 50% ORR, Cardiff said.
Cardiff reported a "deeper tumor response" in those who received a 30 milligram dose compared with those who received 20 milligram.
The safety profiles of both doses are similar, with no major or unexpected toxicities observed, the company added.
The company said it plans to report additional data from the ongoing study in the first half of next year.
Shares of the company were up nearly 40% in recent Tuesday premarket activity.
Price: 3.40, Change: +0.96, Percent Change: +39.34
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。